Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:21:43.435Z.
Calculation as of: 2026-10-06T16:21:43.435Z.
Quote observation: 2026-10-06T16:20:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 781bf18d5b555faf6525e3bbfdfcc877af608ad86c98afd042bd19dc8220ce7c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$149.15M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.95M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $151.58M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $151.66M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $153.40M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $149.34M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.15M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.95M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $157.57M | N/A | 189.93x | 95.49x | 94.46x |
| Immuneering Corporation (IMRX)vs › | $144.85M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $144.10M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $143.91M | N/A | 1490.94x | 1490.94x | 1490.94x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
